Reata Pharmaceuticals, Inc. (NASDAQ:RETA) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Reata Pharmaceuticals, Inc., a ...
Reata Restaurant won’t return to The Tower until July. But we now know how it will look. New, bright vermilion red awnings will line the restaurant’s picture windows along Throckmorton Street and also ...
(Reuters) -Biogen agreed to buy rare disease drugmaker Reata Pharmaceuticals for nearly $6.5 billion, the first large acquisition under new CEO Christopher Viehbacher as he seeks to return the ...
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter investor letter. A copy of the same can be downloaded here. In the ...
Friedrich’s ataxia, an ultra-rare disease characterized by progressively worsening muscle function that ultimately leads to death, now has its first FDA-approved therapy. The regulator has given the ...
It's been a busy October for Reata Pharmaceuticals (RETA +0.00%), which kicked things off Oct. 10 with the announcement that it would end its nine-year partnership with AbbVie (ABBV 2.23%). This move ...
Add Yahoo as a preferred source to see more of our stories on Google. Reata Restaurant won’t return to The Tower until July. But we now know how it will look. New, bright vermilion red awnings will ...
Inside Look stories give Star-Telegram subscribers exclusive sneak peeks and behind-the-scenes reporting. Story suggestion? Editors@star-telegram.com. Reata Restaurant won’t return to The Tower until ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results